Repurposing anticancer drugs for the management of COVID-19

Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are lim...

Descripción completa

Detalles Bibliográficos
Autores principales: El Bairi, Khalid, Trapani, Dario, Petrillo, Angelica, Le Page, Cécile, Zbakh, Hanaa, Daniele, Bruno, Belbaraka, Rhizlane, Curigliano, Giuseppe, Afqir, Said
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508523/
https://www.ncbi.nlm.nih.gov/pubmed/33125946
http://dx.doi.org/10.1016/j.ejca.2020.09.014
_version_ 1783585438260264960
author El Bairi, Khalid
Trapani, Dario
Petrillo, Angelica
Le Page, Cécile
Zbakh, Hanaa
Daniele, Bruno
Belbaraka, Rhizlane
Curigliano, Giuseppe
Afqir, Said
author_facet El Bairi, Khalid
Trapani, Dario
Petrillo, Angelica
Le Page, Cécile
Zbakh, Hanaa
Daniele, Bruno
Belbaraka, Rhizlane
Curigliano, Giuseppe
Afqir, Said
author_sort El Bairi, Khalid
collection PubMed
description Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.
format Online
Article
Text
id pubmed-7508523
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75085232020-09-23 Repurposing anticancer drugs for the management of COVID-19 El Bairi, Khalid Trapani, Dario Petrillo, Angelica Le Page, Cécile Zbakh, Hanaa Daniele, Bruno Belbaraka, Rhizlane Curigliano, Giuseppe Afqir, Said Eur J Cancer Review Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing. Elsevier Ltd. 2020-12 2020-09-22 /pmc/articles/PMC7508523/ /pubmed/33125946 http://dx.doi.org/10.1016/j.ejca.2020.09.014 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
El Bairi, Khalid
Trapani, Dario
Petrillo, Angelica
Le Page, Cécile
Zbakh, Hanaa
Daniele, Bruno
Belbaraka, Rhizlane
Curigliano, Giuseppe
Afqir, Said
Repurposing anticancer drugs for the management of COVID-19
title Repurposing anticancer drugs for the management of COVID-19
title_full Repurposing anticancer drugs for the management of COVID-19
title_fullStr Repurposing anticancer drugs for the management of COVID-19
title_full_unstemmed Repurposing anticancer drugs for the management of COVID-19
title_short Repurposing anticancer drugs for the management of COVID-19
title_sort repurposing anticancer drugs for the management of covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508523/
https://www.ncbi.nlm.nih.gov/pubmed/33125946
http://dx.doi.org/10.1016/j.ejca.2020.09.014
work_keys_str_mv AT elbairikhalid repurposinganticancerdrugsforthemanagementofcovid19
AT trapanidario repurposinganticancerdrugsforthemanagementofcovid19
AT petrilloangelica repurposinganticancerdrugsforthemanagementofcovid19
AT lepagececile repurposinganticancerdrugsforthemanagementofcovid19
AT zbakhhanaa repurposinganticancerdrugsforthemanagementofcovid19
AT danielebruno repurposinganticancerdrugsforthemanagementofcovid19
AT belbarakarhizlane repurposinganticancerdrugsforthemanagementofcovid19
AT curiglianogiuseppe repurposinganticancerdrugsforthemanagementofcovid19
AT afqirsaid repurposinganticancerdrugsforthemanagementofcovid19

Ejemplares similares